HealthDay News — For patients with mild-to-moderate COVID-19, treatment with fluvoxamine does not improve time to sustained recovery vs placebo, according to a study published online January 12 in Journal of the American Medical Association.

Matthew W. McCarthy, MD, PhD, from Weill Cornell Medicine in New York City, and colleagues examined the efficacy of low-dose (50mg twice daily) fluvoxamine for 10 days vs placebo among 1288 patients (674 in the fluvoxamine group and 614 in the placebo group) aged 30 years or older with SARS-CoV-2 infection and experiencing 2 or more symptoms of acute COVID-19 for 7 days or less.

The researchers found that the median time to sustained recovery was 12 and 13 days in the fluvoxamine and placebo groups, respectively (hazard ratio, 0.96; 95 percent credible interval, 0.86 to 1.06). Overall, 3.9 and 3.8% of participants in the fluvoxamine and placebo groups, respectively, had the composite outcome of hospitalization, urgent care visit, emergency department visit, or death through day 28 (hazard ratio, 1.1; 95% CI, 0.5 to 1.8). One and 2 participants in the fluvoxamine and placebo groups, respectively, were hospitalized; there were no deaths reported in either group.

“These findings do not support the use of fluvoxamine at this dose and duration in patients with mild-to-moderate COVID-19,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Editorial